WARSAW — Zimmer Biomet Holdings Inc. announced today, Tuesday, June 14, the pricing of the previously announced underwritten secondary offering of 11,116,533 shares of its common stock by certain of its stockholders, consisting of affiliates of KKR, Goldman Sachs and TPG.

The shares are being sold to the public at an initial price of $115.85 per share. The selling stockholders will receive all of the proceeds of the offering. Neither Zimmer Biomet nor any of its directors, officers or other stockholders is selling any shares of common stock in the offering. The closing of the offering is expected to occur June 16, subject to the satisfaction of customary closing conditions.

Goldman, Sachs & Co. and J.P. Morgan are acting as joint book-running managers and the underwriters for the offering.

Zimmer Biomet has filed a registration statement (including a base prospectus) with the U.S. Securities and Exchange Commission relating to these securities. The offering of these securities was made only by means of a written prospectus forming part of the effective registration statement. The base prospectus and the preliminary prospectus supplement have been filed with the SEC and are available on the SEC’s website.

A copy of the final prospectus supplement related to the offering will be filed with the SEC and may be obtained, when available, from Goldman, Sachs & Co. by contacting Goldman, Sachs & Co., Prospectus Department, 200 W. St., New York, NY 10282, via phone at (866) 471-2526, via fax at (212) 902-9316 or via email at [email protected]; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Ave.,Edgewood, NY 11717, (866) 803-9204.